Pacific northwest udall center of excellence clinical consortium: Study design and baseline cohort characteristics

Brenna A. Cholerton, Cyrus P. Zabetian, Joseph F. Quinn, Kathryn A. Chung, Amie Peterson, Alberto J. Espay, Fredy J. Revilla, Johnna Devoto, G. Stennis Watson, Shu Ching Hu, Karen L. Edwards, Thomas J. Montine, James B. Leverenz

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

Background: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. Objective: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. Methods: Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. Results: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p < 0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. Conclusions: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.

Original languageEnglish (US)
Pages (from-to)205-214
Number of pages10
JournalJournal of Parkinson's Disease
Volume3
Issue number2
DOIs
StatePublished - 2013

Keywords

  • Cognition
  • Parkinson disease
  • cohort studies
  • dementia
  • mild cognitive impairment
  • movement disorders

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Pacific northwest udall center of excellence clinical consortium: Study design and baseline cohort characteristics'. Together they form a unique fingerprint.

Cite this